Switching from Mounjaro to Zepbound: What Changes, What Stays the Same, and How to Talk to Your Provider

Direct answer (40-60 words)

Mounjaro and Zepbound are the same drug, tirzepatide, made by the same manufacturer. The differences are administrative: indication (diabetes vs obesity), insurance category, NDC code, and prescription. Switching is straightforward and requires no dose adjustment, washout, or retitration. You stay at your current dose under a new label.

Table of contents

1. The 30-second answer
2. Why two brands of the same molecule exist
3. What changes when you switch
4. What stays exactly the same
5. The insurance reality
6. The transition process step by step
7. Side effects on the switch
8. Compounded tirzepatide as an alternative
9. When to talk to your provider
10. FAQ
11. Footer disclaimers

Why two brands of the same molecule exist

Tirzepatide is a once-weekly subcutaneous injection developed by Eli Lilly. The molecule is the same regardless of which brand label is on the pen. The FDA approval pathway and the marketing strategy created two products with the same active ingredient.

Mounjaro received FDA approval in May 2022 for the treatment of type 2 diabetes. Zepbound received FDA approval in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol.

The reason for two brands instead of one expanded indication: insurance, payer dynamics, and pricing strategy. Pharmacy benefit managers categorize diabetes drugs differently from anti-obesity medications. Many insurance plans cover diabetes medications but exclude anti-obesity medications. By marketing the same molecule under two brand names with two indications, Lilly can charge different list prices, run different copay assistance programs, and route patients through the appropriate insurance pathway based on their qualifying condition.

The list prices reflect this. Mounjaro and Zepbound are priced almost identically at the wholesale level (around $1,060 to $1,100 per month) but with different rebate structures and savings card programs. The patient experience at the pharmacy depends on which brand the prescription was written for and how the insurance plan classifies it.

This dual-brand structure isn't unique to tirzepatide. Semaglutide is sold as Ozempic for diabetes and Wegovy for weight management. Liraglutide was sold as Victoza for diabetes and Saxenda for weight management. The pattern is consistent across the GLP-1 class.

What changes when you switch

The differences between Mounjaro and Zepbound are administrative and clinical-context-related, not pharmacological.

Indication and label. Mounjaro is approved for type 2 diabetes. Zepbound is approved for chronic weight management. The prescribing information document differs in the dosing recommendations and the trial data referenced. The actual molecule is identical.

NDC (National Drug Code). Each brand has a unique NDC for each dose strength. Pharmacies process them separately, and insurance claims must use the correct NDC.

Insurance category. Mounjaro processes under diabetes coverage, which is included in most plans. Zepbound processes under obesity treatment coverage, which is excluded by many plans (especially Medicare Part D and many state Medicaid programs).

Prescription requirement. Switching requires a new prescription. The old Mounjaro prescription cannot be used to dispense Zepbound. The provider needs to write a new prescription with the new brand name.

Copay savings programs. Lilly runs separate savings card programs for Mounjaro and Zepbound. The Zepbound savings card can bring the price down to $25 per month for commercially insured patients with coverage and around $549 to $650 per month for patients without coverage (for the lower doses, in the Lilly Direct program).

Diagnosis code on the prescription. Mounjaro requires a diabetes diagnosis (typically ICD-10 E11.x for type 2 diabetes). Zepbound requires an obesity or overweight diagnosis (E66.x) typically with a comorbidity code.

Pen color and packaging. The pens look slightly different externally and have different brand colors on the cartons, but the internal device and dosing mechanism are the same.

What stays exactly the same

The clinically relevant features are identical between brands.

Active ingredient. Both contain tirzepatide. The same dual GIP/GLP-1 receptor agonist molecule, made in the same Lilly facilities, to the same pharmaceutical specifications.

Dose strengths. Both come in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pens. The titration schedule is the same (typically 4 weeks per dose level during initiation).

Injection device. The auto-injector pen mechanism is the same single-dose, prefilled, hidden-needle design.

Injection schedule. Once weekly, subcutaneous, in the abdomen, thigh, or upper arm. Same day each week.

Side effect profile. Identical. The same nausea, diarrhea, constipation, decreased appetite, fatigue, and injection site reactions reported in the SURMOUNT-1 trial (Zepbound) and SURPASS trials (Mounjaro). The serious risks (pancreatitis, gallbladder disease, kidney issues, possible thyroid C-cell tumors) are the same.

Drug interactions. Same. Slowed gastric emptying can affect absorption of oral medications, particularly oral contraceptives. The package insert recommends adding a barrier method or switching to a non-oral contraceptive for 4 weeks after starting and 4 weeks after each dose escalation.

Storage. Same refrigerated storage at 36 to 46 degrees Fahrenheit (2 to 8 degrees C). The pen can be kept at room temperature (up to 86 degrees F) for up to 21 days if needed.

Efficacy. Equivalent. The SURMOUNT-1 trial of Zepbound at 15 mg showed an average 20.9 percent body weight reduction over 72 weeks. Mounjaro at the same dose produces the same magnitude of weight loss when used off-label for weight management.

The insurance reality

Insurance coverage is the most common reason patients switch between brands, and it cuts in both directions.

Switching from Mounjaro to Zepbound usually happens when:

• The patient was prescribed Mounjaro off-label for weight loss without a diabetes diagnosis, and the insurer denied coverage or required a step therapy through other diabetes medications.
• The patient now has a documented obesity or overweight diagnosis with a qualifying comorbidity, making them eligible for Zepbound coverage under their plan's anti-obesity benefit.
• The Mounjaro shortage in 2023 and 2024 led some patients to alternative supply pathways. With Zepbound now widely available, the brand-specific pathway is preferred.

Switching from Zepbound to Mounjaro usually happens when:

• The patient develops or has type 2 diabetes alongside obesity, and Mounjaro is covered under the diabetes benefit while Zepbound is not.
• The plan changed coverage rules and now requires Mounjaro for diabetes patients.

Coverage rates as of 2026:

• Commercial insurance coverage for Zepbound: roughly 40 to 50 percent of plans, with prior authorization required in nearly all cases.
• Commercial coverage for Mounjaro: 70 to 85 percent for patients with type 2 diabetes.
• Medicare Part D coverage for Zepbound: not currently included (anti-obesity medications are statutorily excluded), though legislative changes are pending.
• Medicare Part D coverage for Mounjaro: typically covered for type 2 diabetes.
• Medicaid coverage: varies by state. Around 17 states cover Zepbound for obesity in 2026.

For patients who don't qualify for either brand under their insurance, the cash-pay options are Lilly Direct (a direct-to-patient program selling lower-dose Zepbound vials starting around $349 per month) and compounded tirzepatide through a state-licensed compounding pharmacy via a telehealth platform.

The transition process step by step

Switching brands at the same dose is a routine administrative change. Here's how it typically goes:

1. Provider visit (or telehealth equivalent). The provider reviews the indication, confirms eligibility for the new brand based on the patient's diagnosis, and writes a new prescription.

1. Insurance verification. The pharmacy or provider's office checks coverage for the new brand. If prior authorization is required (which is typical for Zepbound), the provider submits the PA paperwork. Approval takes 1 to 14 business days depending on the insurer.

1. First fill of the new brand. The patient picks up the new pen at the same dose they were on with the old brand. No washout period. No retitration. The next scheduled injection day proceeds as normal with the new pen.

1. Continued titration if applicable. If the patient was still in the titration phase (working up from 2.5 to 5 to 7.5 mg), the schedule continues unchanged. The dose levels are the same in both brands.

1. Watch for side effect changes. There shouldn't be any, since the molecule is identical. Some patients report a "fresh start" effect on side effects after a switch, but this is usually a placebo or recall artifact rather than a real pharmacological change.

The most common transition issue is a temporary supply gap. If the new brand is not in stock at the pharmacy or the prior auth takes longer than 7 days, the patient may have a 1-to-2-week gap in dosing. Tirzepatide's half-life is around 5 days, so a 1-week gap usually doesn't cause withdrawal effects but can cause appetite to rebound. Most patients can pick up the schedule without retitration after a 1 to 2 week gap. Gaps longer than 4 weeks may require restarting at a lower dose to avoid GI side effects.

Side effects on the switch

Because the molecule is the same, the side effect profile is the same. The most commonly reported side effects from the SURMOUNT-1 trial of Zepbound 15 mg were:

• Nausea: 28 to 39 percent of patients
• Diarrhea: 19 to 22 percent
• Constipation: 11 to 17 percent
• Vomiting: 8 to 13 percent
• Abdominal pain: 8 to 9 percent
• Injection site reactions: 6 to 7 percent
• Fatigue: 5 to 8 percent
• Burping: 5 to 7 percent

These rates are highest during titration and tend to decline over months of stable dosing. Switching brands at the same dose does not produce a new wave of side effects unless the patient had a meaningful gap between the last Mounjaro dose and the first Zepbound dose. In that case, GI symptoms can briefly recur.

The serious side effects flagged in the boxed warning are the same: possible thyroid C-cell tumors (based on rodent studies, not confirmed in humans), pancreatitis, gallbladder disease, hypoglycemia (mainly when combined with insulin or sulfonylureas), kidney injury (often related to dehydration from GI side effects), severe GI symptoms, hypersensitivity reactions, acute kidney injury, diabetic retinopathy worsening, and possible suicidal thoughts (warning added in 2024 based on post-marketing reports, though randomized trials did not show an increase).

For more on managing GI side effects during titration, see our piece on why GLP-1 medications can cause acid reflux.

Compounded tirzepatide as an alternative

For patients who can't get insurance coverage for either Mounjaro or Zepbound and find Lilly Direct's cash-pay pricing too high, compounded tirzepatide through a state-licensed pharmacy is sometimes considered.

What compounded tirzepatide is: a sterile injectable medication prepared by a compounding pharmacy in response to an individual prescription. The compounding pharmacy sources tirzepatide active pharmaceutical ingredient and prepares it in vials at specified concentrations.

What it isn't: an FDA-approved drug. Compounded medications are not reviewed by the FDA the way brand-name products are. They have not undergone the same testing and are not interchangeable with the brand-name versions.

When compounded versions are legally available: the FDA generally permits compounding of drugs on the FDA Drug Shortage list. Tirzepatide was on the shortage list from late 2022 through October 2024. After Lilly's October 2024 announcement that the shortage had been resolved, the FDA's enforcement position on compounded tirzepatide tightened. As of 2026, only specific 503A and 503B compounding pharmacies operating under particular regulatory frameworks continue to compound tirzepatide for individual patients with documented clinical reasons.

For patients exploring this pathway, FormBlends connects patients with licensed providers and U.S.-based compounding pharmacies. The provider determines whether compounded tirzepatide is appropriate, writes the prescription, and the pharmacy fills it. This is not a substitute for brand-name therapy but an option for patients without insurance coverage who otherwise could not access tirzepatide.

For more on dosing math when working with compounded products, see our piece on units in 2.5 mg of tirzepatide.

When to talk to your provider

Specific situations where switching from Mounjaro to Zepbound merits a provider conversation:

• You have type 2 diabetes plus obesity, and your insurer covers both. Your provider can pick whichever pathway makes more economic sense for you.
• You're currently on Mounjaro off-label for weight loss without a diabetes diagnosis. Zepbound is the on-label option and may be easier to get covered.
• You've been on a stable Mounjaro dose for 6 months or more and are seeing weight regain. The switch to Zepbound shouldn't change efficacy (same drug), but the conversation may surface other interventions.
• You're considering stopping the medication. Either brand stop produces the same withdrawal pattern, with appetite returning over 4 to 6 weeks and weight regain typically starting in months 2 to 6 post-discontinuation.
• You're pregnant or planning pregnancy. Both Mounjaro and Zepbound are not recommended during pregnancy. Discontinuation should be planned with your provider.

The conversation usually takes 5 minutes. The administrative work (new prescription, prior auth submission) takes longer than the clinical decision.

FAQ

Are Mounjaro and Zepbound the same drug?

Yes. Both contain tirzepatide as the active ingredient, made by the same manufacturer (Eli Lilly), in the same dose strengths and the same auto-injector pen. The differences are the FDA-approved indication and the brand label.

Do I need to retitrate when switching from Mounjaro to Zepbound?

No, not if the switch is direct and the dose stays the same. You take your next scheduled injection at the same dose using the new brand. Retitration is only needed if you've had a significant gap (typically 4 weeks or more) between doses.

Why would I switch from Mounjaro to Zepbound?

The most common reason is insurance. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for chronic weight management. If you have obesity but not diabetes, Zepbound is the on-label option and is more likely to be covered for weight management.

Will my side effects change when I switch brands?

No. The molecule is identical, and side effects should be unchanged. If you experience new side effects after a switch, the most likely explanation is a temporary gap in dosing, a recall artifact, or coincidence rather than a real difference between brands.

Is Zepbound more effective than Mounjaro?

No. They contain the same drug at the same doses, so efficacy is equivalent. The SURMOUNT-1 trial of Zepbound showed 20.9 percent average body weight reduction at 72 weeks. The SURPASS-2 trial of Mounjaro showed similar weight loss as a secondary outcome.

What's the cost difference between Mounjaro and Zepbound?

List prices are nearly identical at around $1,060 to $1,100 per month. The out-of-pocket cost varies based on insurance coverage and which copay savings card applies. Lilly Direct sells lower-dose Zepbound vials directly to patients starting at around $349 per month.

Can I switch back to Mounjaro after switching to Zepbound?

Yes. The switch in either direction is administrative. Your provider would write a new prescription, your insurance would re-verify coverage, and you'd continue at the same dose with the new brand label.

Does Zepbound work for diabetes too?

Pharmacologically yes, the molecule is the same and would have the same blood sugar effects. It's not approved or marketed for diabetes, so insurance won't cover Zepbound under the diabetes benefit. Patients with diabetes who want tirzepatide should be prescribed Mounjaro for that indication.

How long does prior authorization take for Zepbound?

Typically 3 to 14 business days for commercial insurance. Some insurers have streamlined PA for obesity medications and can approve in 1 to 2 days. Denials can be appealed, and most providers have templates for the most common denial reasons.

What dose of Zepbound should I take if I was on 10 mg of Mounjaro?

The same dose. 10 mg of Mounjaro and 10 mg of Zepbound are pharmacologically identical. You stay at 10 mg of Zepbound at your next scheduled injection.

Does Zepbound require a higher BMI than Mounjaro?

For coverage purposes, Zepbound is approved for adults with BMI 30 or higher, or BMI 27 or higher with at least one weight-related comorbidity. Mounjaro doesn't have a BMI requirement because it's approved for type 2 diabetes, regardless of weight.

Can I switch from compounded tirzepatide to Zepbound?

Yes, with a new prescription from a provider. The dose math may need to be reviewed because compounded products sometimes use different concentrations than brand-name pens. A provider can map your current compounded dose to the equivalent brand-name pen dose.

Author / review note

Reviewed by the FormBlends Medical Team. This article was last reviewed and updated on April 28, 2026. References cited above include Jastreboff et al., NEJM, 2022 (SURMOUNT-1 tirzepatide for obesity); Frias et al., NEJM, 2021 (SURPASS-2 tirzepatide for type 2 diabetes); the Zepbound and Mounjaro FDA prescribing information; and the FDA Drug Shortage list updates from 2022 to 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly or its subsidiaries.